<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intensive glycemic control prevents severe microvascular disease in patients with type 2 diabetes</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intensive glycemic control prevents severe microvascular disease in patients with type 2 diabetes</h1>
<div class="graphic"><div class="figure"><div class="ttl">Intensive glycemic control prevents severe microvascular disease in patients with type 2 diabetes</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">Kaplan-Meier plots of aggregate endpoints of microvascular disease in patients with type 2 diabetes mellitus in the United Kingdom Prospective Diabetes Study who were randomly assigned to receive either intensive therapy with a sulfonylurea or insulin, or to conventional treatment with diet; drugs were added if the patients had hyperglycemic symptoms or fasting blood glucose concentrations greater than 270 mg/dL (15 mmol/L). Intensive therapy was associated with a 25% reduction (p = 0.01) in the development of microvascular disease, which was defined as kidney failure, death from kidney failure, retinal photocoagulation, or vitreous hemorrhage.</div><div class="graphic_reference">Data from: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.</div><div id="graphicVersion">Graphic 52273 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
